Vanda's spending fell for the first time as Phase III work wrapped up, with the loss beating expectations and revenue climbing 24% year over year. Management now guides full-year revenue above $240 million, with the BYSANTI launch and a December 12 PDUFA date for Quimilza still ahead.
Latest Activity
VNDA Coverage
Friday Afternoon’s Top Analyst Upgrades and Downgrades: BP, Carvana, Iron Mountain, Latch, LivePerson and More
Friday afternoon's top analyst upgrades and downgrades included BP, Carvana, Iron Mountain, Latch and LivePerson.
Amazon, Caterpillar, Disney, EA, Target and More Wednesday Afternoon Analyst Calls
24/7 Wall St. looks at some big analyst calls that we have seen so far on Wednesday, including Amazon, Caterpillar, Disney, EA, Target and more.
Vanda Investors Can Sleep Easy With This FDA Approval
Vanda Pharma shares jumped on Wednesday after the company announced an update from the FDA regarding its treatment for nighttime sleep disturbances associated with Smith-Magenis syndrome.
Vanda Pharma’s Big Step Forward in COVID-19 Pneumonia
Vanda Pharmaceuticals took another big step forward in the fight against COVID-19 on Tuesday morning.
Top Analyst Upgrades and Downgrades: Avaya, Biogen, Broadcom, Chevron, Domino’s, eBay, MGIC, RealReal, Sprout Social, T-Mobile, Zoom, Zynga and More
Tuesday's top analyst upgrades and downgrades included Avaya, Biogen, Broadcom, Chevron, Domino's Pizza, eBay, MGIC Investment, RealReal, Sprout Social, T-Mobile, Zoom Video Communications and Zynga.
Why the FDA Is a Little Slow on This Jet Lag Study
Vanda Pharma shares dropped early to start out the week after the frim announced that it received a Complete Response Letter from the FDA.
Top Analyst Upgrades and Downgrades: Allstate, Corning, DexCom, Lam Research, On Deck, Qualcomm, Spotify, Western Digital, Whiting Petroleum and More
The top analyst upgrades, downgrades and initiations seen on Thursday included Allstate, Corning, DexCom, Lam Research, On Deck, Qualcomm, Spotify, Western Digital and Whiting Petroleum.
Top Analyst Upgrades and Downgrades: AT&T, Caterpillar, Dollar General, EA, Etsy, Facebook, Spirit Airlines, Tesla, Xilinx and More
The top analyst upgrades, downgrades and initiations seen on Thursday included AT&T, Caterpillar, Dollar General, Electronic Arts, Etsy, Facebook, Spirit Airlines, Tesla and Xilinx.
Top Analyst Upgrades and Downgrades: DowDuPont, Electronic Arts, Estee Lauder, Exxon, Generac, Match, Nasdaq, Novartis, PayPal, Snap, Vishay and More
The top analyst upgrades, downgrades and initiations seen on Wednesday included DowDuPont, Electronic Arts, Estee Lauder, Exxon, Generac, Match, Nasdaq, Novartis, PayPal, Snap and Vishay.
Top Analyst Upgrades and Downgrades: Abbott Labs, Apple, Apptio, Cheniere, First Solar, Kratos, Smartsheet, UPS, Waste Management and More
The top analyst upgrades, downgrades and initiations seen on Tuesday included Abbott Laboratories, Apple, Apptio, Cheniere Energy, First Solar, Kratos Defense & Security Solutions, Smartsheet, UPS and Waste Management.
Vanda Pharma Nails Midstage Gastroparesis Study
Vanda Pharmaceuticals shares made a solid gain on Monday after the firm announced results from a midstage trial of patients with idiopathic and diabetic gastroparesis.
Top Analyst Upgrades and Downgrades: AMD, Chevron, GM, Intel, Merck, Nokia, Under Armour and More
The top analyst upgrades, downgrades and other research calls from Monday include AMD, Chevron, GM, Intel, Merck, Nokia and Under Armour.
Top Analyst Upgrades and Downgrades: Alibaba, BHP Billiton, Cintas, Monsanto, Schlumberger, Shopify, Hess, Western Digital and More
The top analyst upgrades, downgrades and other research calls from Tuesday include Alibaba, BHP Billiton, Cintas, Monsanto, Schlumberger, Shopify, Hess and Western Digital.
Jefferies Has 5 Top Biotech Stocks to Buy for 2017
Needless to say, the past two years have been rough on biotech. The question for investors is which of the stocks hold the best potential in 2017.
Top Biotech Plays Highlight Jefferies Growth Stocks to Buy
Jefferies highlights top growth stocks to buy each week, and this week is no exception. These four all make good sense now and have outstanding upside potential.